By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Provectus Biopharmaceuticals Inc. 

7327 Oak Ridge Highway Suite B

Knoxville  Tennessee  37931  U.S.A.
Phone: 866-594-5999 Fax:


Company News
Provectus Biopharmaceuticals Inc. Reports Publication Of Review Paper On PV-10 Tumor Ablation And Immune Stimulation 9/29/2015 11:18:49 AM
Provectus Biopharmaceuticals Inc. Announces Initiation Of Phase Ib/II Clinical Trial To Study PV-10 In Combination With Immune Check Point Inhibitor Pembrolizumab 9/23/2015 11:15:37 AM
Provectus Biopharmaceuticals Inc. Completes Patient Accrual For PH-10 Phase II Clinical Study Of Cellular And Immunologic Changes In The Skin 9/21/2015 11:19:43 AM
Provectus Biopharmaceuticals Inc. Awarded U.S. Patent Protecting Use Of PV-10 As Part Of Combination Therapy For Cancer 8/18/2015 8:38:41 AM
Provectus Biopharmaceuticals Inc. Reports Second Quarter 2015 Financial Results 8/6/2015 12:03:45 PM
Provectus Biopharmaceuticals Inc. Will Hold Its 2015 Second Quarter Business Update Conference Call On Thursday, August 6, 2015, At 4 PM Eastern Daylight Time 7/22/2015 10:36:36 AM
Provectus Biopharmaceuticals Inc., Sinopharm-China State Institute Of Pharmaceutical Industry And Sinopharm A-Think Pharmaceutical Co., Ltd Continue Search For Agreement On PV-10 Use In China 7/16/2015 11:10:49 AM
Provectus Biopharmaceuticals Inc.’ Data On PV-10 For Chemoablation Of Liver Cancers Presented At ESMO 17th World Congress On Gastrointestinal Cancer 7/2/2015 11:17:03 AM
Provectus Biopharmaceuticals Inc. Signs Letter Of Intent With Boehringer Ingelheim (China) To Collaborate In Bringing PV-10 To Market In China 7/2/2015 9:28:26 AM
Provectus Biopharmaceuticals Inc.’ Data On PV-10 As Treatment For Melanoma Presented At 5th European Post-Chicago Melanoma / Skin Cancer Meeting 6/26/2015 2:29:47 PM